Bastiaan De Leeuw has been active in the field of drug delivery for the last 20 years. He has led projects covering dry-powder formulation development, inhaler design and development, and auto-injector design and development, as well as the associated stages of clinical and regulatory evaluations. In addition, he led the initial clinical evaluation of urologic diagnostic tests at NovioGendix (now MDxHealth) and has worked at Focus Inhalation, Akela Pharma, Oval Medical, and Bespak. Bastiaan has a degree in biopharmaceutical sciences, focussing on polymeric drug delivery systems for the formulation of proteins and peptides. His research combined pharmaceutical technology and pharmacology in industry-sponsored projects. 

Mark A. Chipperfield spent 20 years working within large pharma (GSK, Sanofi Aventis, Novartis, Roche) in the field of drug delivery devices and special purpose packaging. Throughout his career, he has been heavily involved in the development of combination products in several forms: solution/suspension inhalers, multi-dose disposable and reusable dry powder inhalers, convenience kits, pen-injectors, auto-injectors, dispensers and special purpose applicators. Since 2015, he has been an independent consultant supporting pharma companies, suppliers and device innovators across the globe to develop, launch, and maintain their products.

Dr. Oliver K. Valet is one of the co-founders of rap.ID Particle Systems GmbH a company that develops manufactures and sells unique particle identification systems. Within the last 15 years their patented technology fuses particle isolation, imaging analysis and spectroscopic technology together to powerful investigation tools. Streamlining particle contamina­tion identification and particle characterization. Within rap.ID Dr. Valet is responsible for the product development and worldwide marketing and sales. From the FDA inspected industrial forensics laboratory work per­formed at both rap.ID sites in Berlin, Germany and Princeton, New Jersey Dr. Valet has more than a decade experience in the field of industrial and environmental chemical analysis on particles. As an active member of the Respiratory Drug Delivery, RDD, the Royal Chemical Society, Parenteral Drug Association, PDA and American Association of Pharmaceutical Sci­ence, AAPS and the Apothekerverband, APV he has published his work continuously and presented on various conferences.

Klaus Ullherr, Senior Product Manager, has a degree in electrical engineering. After university he worked as a project manager in the electrical industry for several years. In March 2000, he joined Robert Bosch GmbH, Packaging Technology, Product Divi­sion Pharma Liquid. During the first two years, he was project manager responsible for handling complex customer orders. Since 2002, he is product manager for the business fields syringes and filling systems with global product responsibility. His main functions are: market analysis, initiating new product developments, business devel­opment, and expert for syringe processing. He is a member of the “PDA Interest Group pre-filled syringes” and works as an expert in the DIN/ISO group for primary packaging. Klaus is also member of ISPE and co-track-leader of the yearly ISPE Aseptic Conference. He is a well-known speaker on conferences covering trends and solutions for fill/finish equipment especially for pre-filled syringes, other pre-sterilized contain­ers, and single-use-filling-systems

Dr. Stephen A. Barat is the head of pre-clinical development and early clinical development for Scynexis, a biotechnology company focusing on development and commercialization of novel anti-infective treatments for life-threatening infections. He is a member of the Scynexis senior management team and has 20 years of experience in global drug devel­opment and registration from large multi-national pharmaceutical com­panies. Dr. Barat is a member of the PQRI working group for leachables and extractables for parenteral drug products and a member of the USP expert panel for biocompatibility testing. He has been an invited speaker and avid participant in various international venues on pharmaceutical development and a contributor to many continuing education courses, particularly in the area of safety assessment of impurities.

Ian Thompson has been with Ypsomed AG, formerly Disetronic AG, since 1995 in a number of roles, including key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-83, working initially in commercial roles for fermentation technology. He has worked in medical device companies since moving to Switzerland in 1990. Since 2003, his main focus has been business development and new product innovation leading to the successful development and launch of a range of new pen and autoinjector custom products for Ypsomed Delivery Systems. Ypsomed Delivery Systems continues to focus on the development and manufacturing of next-generation pen, autoinjector, and wearable injector technologies.